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Abstract
Background: Clear cell renal cell carcinomas (ccRCCs) constitute the most common renal carcinomas,
characterized by a relatively aggressive clinical course. Thus, scientific research is targeting towards the
identification of immunohistochemical and molecular markers that could be useful regarding diagnosis,
appropriate therapy and prediction of prognosis. In the present study we assessed and correlated the
expression of caspase-8, phosphorylated p38 mitogen-activated protein kinase (p-p38) and bcl-2 protein
with histopathological features and clinical outcome of 27 patients with ccRCCs.
Method: Immunohistochemistry in formalin-fixed and paraffin-embedded tissue sections was performed.
The associations among various features were assessed utilizing statistical analysis.
Results: We found that increased expression of cytoplasmic caspase-8 and bcl-2 protein was strongly
associated with low Fuhrman's grade of carcinomas (p = 0.019 and p = 0.041, respectively). On the other
hand, increased p-p38 expression was significantly related to high Fuhrman's grade (p = 0.006). Moreover,
high bcl-2 expression was correlated with low pathological stage of ccRCCs (p = 0.026). Increased
expression of cytoplasmic caspase-8 as well as low-grade tumors (grade 1 and 2) implied a greater
probability of patients' survival, in univariate statistical analysis (p = 0.037 and p = 0.019, respectively).
Neither p-p38 nor bcl-2 expression was significantly linked to patients' survival. There were not emerged
statistically significant associations among caspase-8, p-p38 kinase and bcl-2 protein.
Conclusion: For the first time the prognostic impact of caspase-8 and p-p38 was studied in a series of
ccRCCs, using immunohistochemistry in formalin-fixed and paraffin-embedded tissue sections. The
suggestive relationship of caspase-8 with patients' clinical outcome, as well as the role of p-p38 within
different grade categories, mandates further studies in larger cohorts of RCCs.
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Background
Conventional (clear) RCCs (ccRCCs) are characterized by
their relatively poor prognosis due to late presentation
and resistance to various therapeutical manipulations [1].
Thus, the identification of new immunohistochemical
and molecular markers that could provide better prognos-
tic information for each patient is needed. In this context,
the role of factors, such as bcl-2 protein, caspases and
mitogen-activated protein kinases (MAPKs), influencing
cell survival-proliferation and apoptosis, has not been
fully understood yet, within ccRCCs.
Bcl-2 is an intracellular membrane protein capable of
blocking the programmed cell death through regulation
of the mitochondrial apoptotic pathway [2,3]. Although
bcl-2 is frequently upregulated in RCCs, studies of its exact
relationship with patients' clinicopathological features
have given controversial results thus far [4-6].
Caspases are proteases characterized by their essential
action in the apoptotic pathway [7]. Caspase-8, particu-
larly, plays a decisive role as an initiator caspase in the
extrinsic apoptotic pathway since its activation leads to
caspase-3 activation and accordingly to apoptosis [7].
However, bibliographical data regarding caspase-8 immu-
nohistochemical expression in RCCs are limited [8-10].
p38, a member of the MAPKs group, participates in a sig-
naling cascade regulating cellular responses to cytokines
and stress and seems to play a role in cell proliferation and
apoptosis within RCCs [11,12]. Few former studies
assessed the immunohistochemical expression of p38 in
RCCs but the impact of activated (phosphorylated) p38
(p-p38) on patients' survival has not been described yet
[12,13].
Experimental data suggest that p38 pathway may function
both upstream and downstream of caspases (including
caspase-8) in the apoptotic response [14,15]. Moreover,
p38 kinase appears to play a crucial role regarding bcl-2
phosphorylation and its subsequent inactivation, leading
to an increased apoptotic effect [16,17]. Nevertheless, this
dual, yet controversial, function of p38 kinase which links
three different apoptotic pathways has never been studied
within RCCs.
The purpose of our study was to assess and compare the
immunohistochemical expression of p-p38, bcl-2 and cas-
pase-8 in ccRCCs, identifying any associations with Fuhr-
man's grade, pathological stage and patients' clinical
outcome. To our knowledge this is the first study attempt-
ing to explore the specific prognostic influence of p-p38
and caspase-8 immunohistochemical expression within
ccRCCs.
Method
27 patients with ccRCCs [15 men and 12 women, mean
age at operation: 58.15 years (range: 42–77)] underwent
radical nephrectomy between 1999 and 2003 at our Hos-
pital. Follow-up information was available in all cases,
informed consent was obtained from all patients and the
study was approved by the scientific committee of the
Hospital. The mean time of follow-up was 70.63 months
(range: 11–105), during which 4 patients died of the dis-
ease [mean survival: 40.75 months (range: 11–54)]
whereas 23 were alive [mean follow-up: 75.83 months
(range: 44–105)].
All specimens were formalin-fixed and paraffin-embed-
ded. For each patient, one representative block containing
more than 80% of neoplastic tissue was histopathologi-
cally evaluated. All tumors were graded according to Fuhr-
man's grading system [18] as: grade 1 (n = 7), grade 2 (n
= 13), grade 3 (n = 4) and grade 4 (n = 3). The pathologi-
cal stage (pT-stage) was determined using the TNM classi-
fication of malignant tumors [19] as: pT1a (n = 5), pT1b
(n = 6), pT2 (n = 8), pT3a (n = 5) and pT3b (n = 3).
p-p38, bcl-2 and caspase-8 immunostaing was performed
in representative sections, cut at 3 μm, using Bond-maX
system (Vision BioSystems Ltd, Australia) according to the
manufacturer's instructions. The following antibodies
were used: anti-phopsho-p38 MAPK (clone 12F8, rabbit
mAb, Cell Signaling Technology Inc. USA, diluted: 1/
100), anti-bcl-2 protein (clone 124, mouse mAb, Dako
Cytomation, Denmark, diluted: 1/50) and anti-caspase-8
(clone 11B6, mouse mAb, Novocastra, UK, diluted: 1/30).
Under light microscope, p-p38 and bcl-2 immunostain-
ing was estimated as the percentage of neoplastic cells
with nuclear and cytoplasmic reactivity, respectively, out
of the total number of neoplastic cells counted. The same
method was also applied for the assessment of cytoplas-
mic caspase-8 immunostaining. However, because of a
marked intratumoral heterogeneity of its expression, a
score was given to sections based on the estimated per-
centage of immunopositive cells (1 = ≤25%, 2 = 26–50%,
3 = 51–75%, 4 = >75%) and on the intensity of the immu-
nostaining (1 = no staining or weak, 2 = moderate, 3 =
strong, 4 = very strong). A final combined score of immu-
nostaining was then calculated by adding both scores
(weak = score 2–3, moderate = score 4–6, strong = score
7–8). The presence or absence of nuclear caspase-8 stain-
ing was also assessed separately and scored as positive or
negative (>10% or ≤ 10% positive cells out of the total
number of neoplastic cells counted, respectively).
For statistical calculations, p-p38 expression and bcl-2
cytoplasmic expression as well as patients' age were
treated as continuous variables. Cytoplasmic and nuclearDiagnostic Pathology 2009, 4:7 http://www.diagnosticpathology.org/content/4/1/7
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caspase-8 expression, tumor grade, pT-stage and patients'
sex were analyzed as categorical variables. Associations
among continuous variables were tested using Spearman's
rank correlation coefficient whereas correlations among
categorical variables using Chi-square or Fisher's exact
test, as appropriate. The relationship between a continu-
ous and a categorical variable was examined using
Kruskal-Wallis ANOVA test or Mann-Whitney U-test, as
appropriate.
Univariate survival analysis was performed using death
due to disease as the endpoint. The effect of the various
features on clinical outcome was assessed by plotting sur-
vival curves according to Kaplan-Meier method and com-
paring groups with the Log-rank test. Continuous
variables were categorized on the basis of the median
value rounded at its nearest 10%. Caspase-8 cytoplasmic
expression was treated as a categorical variable (weak ver-
sus moderate/strong) as well as patients' gender. Grade
and pT-stage were categorized in two groups (grade 1–2
versus grade 3–4 and pT1a-pT1b-pT2 versus pT3a-pT3b,
respectively) due to the different biological behavior of
these groups within ccRCCs [20,21]. All statistical calcula-
tions were completed using the statistical package SPSS,
version 13.0, for Windows Software (SPSS, Chicago, Illi-
nois, USA). Differences were considered statistically sig-
nificant when p-value (two-sided) was < 0.05.
Results
Caspase-8, p-p38 and bcl-2 expression
Caspase-8 cytoplasmic expression was detected in 27/27
cases [percentage of positive neoplastic cells: 15%–90%
(mean value: 48.85%)] [Fig. 1]. Thus, the cytoplasmic
score was as follows: score 1 (n = 7 cases), score 2 (n = 8),
score 3 (n = 8), score 4 (n = 4). The intensity of cytoplas-
mic staining was as follows: score 1 (n = 2), score 2 (n =
8), score 3 (n = 9), score 4 (n = 8). Therefore, the final cas-
pase-8 combined cytoplasmic score was: score 1 (weak
immunostaining: n = 5), score 2 (moderate immunostain-
ing: n = 13), score 3 (strong immunostaining: n = 9). Con-
cerning nuclear immunoreaction, 18/27 cases were
categorized as positive whereas the remaining cases were
negative.
p-p38 was detected in 24/27 cases and was exclusively
localized in the nuclei of malignant cells [percentage of
positive neoplastic cells: 1%–85% (mean value: 19.59%)]
[Fig. 1].
Bcl-2 cytoplasmic immunoreactivity was detected in 27/
27 cases [percentage of positive neoplastic cells: 5%–80%
(mean value: 45.19%)] [Fig. 2].
Correlations among factors and Fuhrman's grade
In our cohort, cytoplasmic caspase-8 was negatively asso-
ciated with grade in a statistically significant level [Fisher's
Exact Test, p = 0.019]. Nuclear caspase-8 was not con-
nected with grade [Fisher's Exact Test, p = 0.424].
p-p38 expression significantly increased from grade 1
through grade 4 tumors [Kruskal Wallis test, p = 0.006]
[Fig. 3].
Bcl-2 expression was inversely associated with grade in a
statistically significant level [Kruskal Wallis test, p =
0.041] [Fig. 4].
Finally, patients' age and gender were unrelated to grade,
in our series [Kruskal Wallis Test, p = 0.601 and Fisher's
Exact Test, p = 0.845, respectively].
Correlations among caspase-8, p-p38, bcl-2 and pT-stage
Bcl-2 expression was inversely associated with pT-stage in
the entire cohort [Kruskal Wallis test, p = 0.026].
p-p38 as well as cytoplasmic and nuclear caspase-8 were
not significantly associated with pT-stage in our group
[Kruskal Wallis test/p = 0.604, Fisher's Exact Test/p =
0.605 and p = 0.302, respectively].
Patients' age and gender as well as grade were not statisti-
cally related to pT-stage [Kruskal Wallis Test/p = 0.714,
Fisher's Exact Test/p = 0.623, Fisher's Exact Test/p = 0.101,
respectively].
Correlations among caspase-8, p-p38, bcl-2, age and 
gender
No statistically significant associations were detected
among p-p38, caspase-8, bcl-2, patients' age and gender.
However, high p-p38 expression tended to be associated
with low immunopositivity for cytoplasmic caspase-8 and
high immunoreactivity for nuclear caspase-8 [Kruskal
Wallis Test, p = 0.202 and p = 0.523, respectively]. p-p38,
also, tended to be inversely related to bcl-2 expression
[Spearman's rank correlation coefficient, p = 0.433].
Survival analysis
Univariate analysis demonstrated that higher cytoplasmic
caspase-8 [Log Rank Test, weak versus moderate/strong, p
= 0.037] as well as lower grade [Log Rank Test, grade 1 and
2 versus grade 3 and 4, p = 0.019] implied a greater prob-
ability of survival, in the series of 27 patients [Fig. 5, Table
1].
The mean survival time of patients with high (moderate/
strong) cytoplasmic caspase-8 immunoreactivity was
72.77 months whereas the corresponding time for
patients with weak caspase-8 cytoplasmic immunoreactiv-Diagnostic Pathology 2009, 4:7 http://www.diagnosticpathology.org/content/4/1/7
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ity was 52 months. The mean survival time of patients
with low-grade tumors (grade 1 and 2) was 74.40 months
while patients with high-grade neoplasms (grade 3 and 4)
characterized by a mean survival of 59.86 months.
The remaining features (age, gender, pT-stage, p-p38,
nuclear caspase-8, bcl-2) were not significantly related to
patients' survival [Table 1].
Discussion
In the present study, we observed a significant negative
association of cytoplasmic caspase-8 with grade of
ccRCCs; cytoplasmic caspase-8 was highest in low-grade
tumors, in contrast to previous studies in breast and lung
carcinomas [22,23]. This negative relationship implies
that caspase-8 exerts an apoptotic action within low-grade
ccRCCs, hence enhanced cytoplasmic distribution in
grade 1 and 2 tumors. Our results seem to reflect the proc-
ess in which malignant cells of high-grade specimens
simultaneously display enhanced proliferative and
decreased apoptotic activity [5,24].
A significant association was noted between increased cas-
pase-8 cytoplasmic expression and better patients' sur-
p-p38 and caspase-8 expression in ccRCC Figure 1
p-p38 and caspase-8 expression in ccRCC. A): (p-p38 X400). p-p38 nuclear expression in few malignant cells in a grade 1 
ccRCC. B): (p-p38 X400). High p-p38 nuclear expression from the majority of neoplastic cells in a grade 4 ccRCC. C): (cas-
pase-8 X400). Strong cytoplasmic and nuclear expression of caspase-8 in a grade 1 ccRCC. D): (caspase-8 X400). Weak cyto-
plasmic as well as nuclear expression of caspase-8 in a grade 4 ccRCC. ccRCC: clear cell renal cell carcinoma.Diagnostic Pathology 2009, 4:7 http://www.diagnosticpathology.org/content/4/1/7
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vival. This implication has never been reported in RCCs
and is in agreement to recently published findings in pap-
illary thyroid carcinomas [25].
p-p38 was detected in the majority of carcinomas local-
ized in the nuclei of the malignant cells, in agreement
with a previous study in ccRCCs [12]. Increased p-p38
expression was positively related to high grade ccRCCs, in
line with studies performed in a variety of tumors [26,27].
To our knowledge, this is the first study in ccRCCs demon-
strating this kind of association.
In contrast to published data regarding the apoptotic and
anti-proliferative action of p-p38 in RCCs, our results sug-
gest that p-p38 seems to exhibit a proliferative or anti-
apoptotic action, being increased in high-grade tumors
[11]. This finding is also strengthened by the identifica-
tion of decreased expression of the apoptotic cytoplasmic
caspase-8 with increasing the degree of malignancy within
our group. Indeed, investigators have showed that bone
morphogenetic protein 6 played its anti-apoptotic effect
in breast cancer through activation of p38 pathway [28].
We additionally detected, in harmony with others, a sig-
nificant inverse relationship between bcl-2 expression and
Bcl-2 expression in ccRCC Figure 2
Bcl-2 expression in ccRCC. A): (Bcl-2 X400). Strong cytoplasmic expression of bcl-2 protein in a grade 1 ccRCC. B): (Bcl-
2 X400). Weak cytoplasmic expression of bcl-2 protein in a few malignant cells in a grade 3 ccRCC. Note also the positive 
inflammatory cells. ccRCC: clear cell renal cell carcinoma.Diagnostic Pathology 2009, 4:7 http://www.diagnosticpathology.org/content/4/1/7
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grade as well as pT-stage of RCCs [6,29]. A possible expla-
nation to this might be based on the suggested antiprolif-
erative role of bcl-2 protein [6,30]. This function, which
seems to be distinct from its well-known antiapoptotic
action, has been reported in various malignancies [31,32].
Therefore, it could be hypothesized that high expression
of bcl-2 prevents cell proliferation, suppresses tumor
growth and thereby is associated with a lower grade and
pT-stage in RCCs, as previously stated [6].
Provided that a possible but not yet adequately studied
mechanism, linking the p38 pathway with caspases activ-
ity has been previously implied [14,15], we attempted to
correlate the expression of caspase-8 and p-p38 in our
series of RCCs. In this framework, researchers have sug-
gested that caspase-8 is essential for the activation of the
p38 pathway through death receptors [33], while others
pointed out that an enhanced activation of p38 kinase
pathway may result in caspase-8 activation and enhance-
ment of apoptosis, based on experiments in a human
astrocytoma cell line [34].
However, no statistically significant associations between
cytoplasmic or nuclear caspase-8 and p-p38 were revealed
in our work, but only a suggestive negative and positive
relationship, respectively. These findings backup our
aforesaid hypothesis regarding the apoptotic action of
cytoplasmic caspase-8 and proliferative or anti-apoptotic
role of p-p38 within our ccRCCs [28,35]. Moreover, we
cannot exclude a potential inhibitory effect of p38 signal-
ing upon caspase activity, as it has been previously
reported [36]. The reason however, for the increased,
though statistically insignificant, expression of nuclear
caspase-8 in parallel with high p-p38 immunoreactivity, is
still to be determined.
As regards p-p38 and bcl-2 association, no strong linkage
was identified in our study. However, p-p38 tended to be
inversely related to bcl-2 expression. In this context, scien-
tists have stressed that p38 can induce apoptosis via phos-
phorylation of bcl-2 [16,17]. Concerning RCCs, there are
no related studies. According to our work, the negative,
though loose, correlation found between p-p38 and bcl-2,
constitutes an early indication of a probable antagonistic
Schematic illustration of the relationship of p-p38 expression  with Fuhrman's grade of 27 clear cell renal cell carcinomas Figure 3
Schematic illustration of the relationship of p-p38 
expression with Fuhrman's grade of 27 clear cell 
renal cell carcinomas. p-p38 expression increases with 
increasing grade in the entire cohort.
Schematic illustration of the relationship of bcl-2 expression  with Fuhrman's grade of 27 clear cell renal cell carcinomas Figure 4
Schematic illustration of the relationship of bcl-2 
expression with Fuhrman's grade of 27 clear cell 
renal cell carcinomas. Bcl-2 expression is inversely associ-
ated with grade in the entire cohort.Diagnostic Pathology 2009, 4:7 http://www.diagnosticpathology.org/content/4/1/7
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interaction of these two factors within ccRCCs. The major
question to be identified is whether this interaction con-
cerns the proliferative, the apoptotic or both potential
functions of these factors.
No statistically important correlation between bcl-2 and
caspase-8 was found. This was expected, since these sub-
stances act through different apoptotic pathways [3,7]. We
also demonstrated that low-grade tumors (grade 1 and 2)
depicted greater probability of survival in comparison to
high-grade (grade 3 and 4), in accordance with previous
data [20,21]. The absence of statistical significance regard-
ing the association of pT-stage with prognosis could be
attributed to the small cohort.
Conclusion
Conclusively, caspase-8 pro-apoptotic function appears to
prevail in low-grade ccRCCs and seems to be associated
with a better clinical outcome. However, the specific role
of cytoplasmic and nuclear caspase-8 needs to be identi-
fied. Moreover, p-p38 seems to exert a proliferative rather
than an apoptotic role within ccRCCs and is associated
with an aggressive phenotype. Finally, the common antia-
poptotic role of bcl-2 protein is extremely complicated
within ccRCCs and appears to be influenced by other syn-
ergic and/or antagonistic pathways. In this regard, p38
MAPK signaling may be of fundamental importance. p38,
caspase-8 and bcl-2, though seemingly distinct compo-
nents of three discrete signaling pathways implicated in
cell growth and apoptosis, appear to be characterized, to
some extent, by an interrelationship. p38 seems to bridge
the above pathways and, in specific tissue substrates, reg-
Kaplan-Meir survival curves in 27 patients with clear cell renal cell carcinomas according to: A) Cytoplasmic caspase-8 expres- sion [green line indicates high expression (moderate/strong) while blue line low expression (weak)] Figure 5
Kaplan-Meir survival curves in 27 patients with clear cell renal cell carcinomas according to: A) Cytoplasmic 
caspase-8 expression [green line indicates high expression (moderate/strong) while blue line low expression 
(weak)]. B) Fuhrman's grade [green line indicates high grade (3 and 4) while blue line low grade (1 and 2)]. According to the 
statistical analysis, Fuhrman's grading is more significant as a prognosticator than caspase-8 cytoplasmic expression. Cum sur-
vival: probability of being a patient alive. Time (months): months since diagnosis.Diagnostic Pathology 2009, 4:7 http://www.diagnosticpathology.org/content/4/1/7
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ulates the balance between apoptotic cell death and pro-
liferation. Prospective, larger, experiments are of utmost
importance towards the elucidation of the exact clinical
role and associations among caspase-8, p-p38 and bcl-2
within the various subtypes as well as the different grade
and stage categories of RCCs.
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